BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21512397)

  • 1. Sensitive angiogenesis imaging of orthotopic bladder tumors in mice using a selective magnetic resonance imaging contrast agent containing VEGF121/rGel.
    Cho EJ; Yang J; Mohamedali KA; Lim EK; Kim EJ; Farhangfar CJ; Suh JS; Haam S; Rosenblum MG; Huh YM
    Invest Radiol; 2011 Jul; 46(7):441-9. PubMed ID: 21512397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel.
    Hsu AR; Cai W; Veeravagu A; Mohamedali KA; Chen K; Kim S; Vogel H; Hou LC; Tse V; Rosenblum MG; Chen X
    J Nucl Med; 2007 Mar; 48(3):445-54. PubMed ID: 17332623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors.
    Mohamedali KA; Kedar D; Sweeney P; Kamat A; Davis DW; Eve BY; Huang S; Thorpe PE; Dinney CP; Rosenblum MG
    Neoplasia; 2005 Oct; 7(10):912-20. PubMed ID: 16242074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
    Mohamedali KA; Poblenz AT; Sikes CR; Navone NM; Thorpe PE; Darnay BG; Rosenblum MG
    Cancer Res; 2006 Nov; 66(22):10919-28. PubMed ID: 17108129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein.
    Akiyama H; Mohamedali KA; E Silva RL; Kachi S; Shen J; Hatara C; Umeda N; Hackett SF; Aslam S; Krause M; Lai H; Rosenblum MG; Campochiaro PA
    Mol Pharmacol; 2005 Dec; 68(6):1543-50. PubMed ID: 16150930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Photochemical internalization augments tumor vascular cytotoxicity and specificity of VEGF(121)/rGel fusion toxin.
    Weyergang A; Cheung LH; Rosenblum MG; Mohamedali KA; Peng Q; Waltenberger J; Berg K
    J Control Release; 2014 Apr; 180():1-9. PubMed ID: 24531010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of biologically active VEGF121 fusion proteins in Escherichia coli.
    Kim S; Mohamedali KA; Cheung LH; Rosenblum MG
    J Biotechnol; 2007 Feb; 128(3):638-47. PubMed ID: 17218033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo MR/optical imaging for gastrin releasing peptide receptor of prostate cancer tumor using Gd-TTDA-NP-BN-Cy5.5.
    Lin YH; Dayananda K; Chen CY; Liu GC; Luo TY; Hsu HS; Wang YM
    Bioorg Med Chem; 2011 Feb; 19(3):1085-96. PubMed ID: 20493715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Light-enhanced VEGF
    Weyergang A; Fremstedal AS; Skarpen E; Peng Q; Mohamedali KA; Eng MS; Cheung LH; Rosenblum MG; Waltenberger J; Berg K
    J Control Release; 2018 Oct; 288():161-172. PubMed ID: 30217739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging.
    Winter PM; Caruthers SD; Kassner A; Harris TD; Chinen LK; Allen JS; Lacy EK; Zhang H; Robertson JD; Wickline SA; Lanza GM
    Cancer Res; 2003 Sep; 63(18):5838-43. PubMed ID: 14522907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
    Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
    Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Folate-poly-L-lysine-Gd-DTPA as MR contrast agent for tumor imaging via folate receptor-targeted delivery].
    Yuan Z; Liu SY; Xiao XS; Zhong GR; Jiang QJ
    Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(10):673-8. PubMed ID: 17553304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the VEGF, bFGF, aFGF and IL8 angiogenic activity in urinary bladder carcinoma, using the mice cutaneous angiogenesis test.
    Rogala E; Skopińska-Rózewska E; Sommer E; Pastewka K; Chorostowska-Wynimko J; Sokolnicka I; Kazoń M
    Anticancer Res; 2001; 21(6B):4259-63. PubMed ID: 11908679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
    Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
    Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
    Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
    Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.